Trial Profile

A clinical trial of ERX-41 for solid cancers

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 08 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ERX 41 (Primary)
Indications Breast cancer; Glioblastoma; Ovarian cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions
Sponsors EtiraRx

Most Recent Events

08 Jun 2022 New trial record
02 Jun 2022 According to an Etirarx media release, the company plans to initiate clinical trials of ERX 41 as early as the first quarter of 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com